[HTML] cell.comFull View

[HTML][HTML] MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer cell, 2018 - cell.com
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …
被引用次数：113 相关文章

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi… - Cancer …, 2018 - scholars.uthscsa.edu
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …

[引用][C] MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - 2018 - corc.ac.cn
中国开放科研知识云: MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring
cRaf-Independent MEK Activation 验证码: 换一张 忘记密码? 记住我 取消 登录 CORC 首页 …
[PDF] academia.edu

[PDF][PDF] MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer Cell, 2018 - academia.edu
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer Cell, 2018 - europepmc.org
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …

[引用][C] MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer Cell, 2018 - cir.nii.ac.jp
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK
Activation | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[HTML] sciencedirect.com

[HTML][HTML] MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer Cell, 2018 - Elsevier
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …
[HTML] cell.com

[HTML][HTML] MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer Cell, 2018 - cell.com
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi… - Cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …
[HTML] nih.gov

[HTML][HTML] MAST1 drives cisplatin resistance in human cancers by rewiring cRaf independent MEK activation

L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang… - Cancer cell, 2018 - ncbi.nlm.nih.gov
Platinum-based chemotherapeutics represent a mainstay of cancer therapy, but resistance
limits their curative potential. Through a kinome RNAi screen, we identified microtubule …